OKLO

Oklo’s stock has fallen 61% this year, even though the company has reached a significant technical milestone. The article points out a disconnect between the company’s scientific progress and its market performance.

SANTA CLARA, Calif., October 23, 2026--Oklo Inc. (NYSE: OKLO) ("Oklo," or "the Company"), an advanced nuclear technology company, today announced it will release its financial results and provide business updates for the third quarter ended September 30, 2026, before market opens on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. Eastern Time (5:30 a.m.

Key TakeawaysOklo shares fell 4% today after Truist cut its price target to $31 from $51 and kept its Hold rating ahead of third-quarter results. Truist is the fourth firm in four days to cut its Oklo target, after Piper Sandler, Barclays and Citi, and none of the four changed its rating.

Oklo is developing its Groves 2 Forge isotope production facility under the U.S. Department of Energy’s National Reactor Innovation Center program. The project aims to supply medical isotopes for radiopharmaceutical use and positions Oklo among firms working on next‑generation reactor concepts.

Oklo has shed more than 60% of its value this year and sits near a 52-week low, yet its customer pipeline spans gigawatts and its regulatory path just cleared a major hurdle. Whether that combination makes it a bargain or a trap depends on a few critical milestones still ahead.

Truist Securities keeps a Hold rating on Oklo and cuts its price target from $51 to $31. The downgrade reflects the analyst’s view of the company’s current valuation.

Wall Street analysts are discussing Oklo along with other small modular reactor and nuclear energy companies during the third‑quarter earnings season. The focus includes Oklo, NuScale Power, Constellation Energy, Vistra, and Centrus Energy.

Citigroup maintains a Neutral rating on Oklo and lowers its price target from $57.5 to $33. The change reflects the bank’s updated assessment of the stock’s outlook.